Get the Stockscreener App
12.50
5.59%
-0.74
Alpha Tau Medical Ltd stock is traded at $12.50, with a volume of 364.40K.
It is down -5.59% in the last 24 hours and up +24.38% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
See More
Previous Close:
$13.24
Open:
$13.47
24h Volume:
364.40K
Relative Volume:
0.41
Market Cap:
$1.13B
Revenue:
-
Net Income/Loss:
$-56.88M
P/E Ratio:
-18.93
EPS:
-0.6604
Net Cash Flow:
$-39.43M
1W Performance:
-7.75%
1M Performance:
+24.38%
6M Performance:
+78.83%
1Y Performance:
+313.91%
1-Day Range:
$12.38
$13.50
1-Week Range:
$12.38
$13.90
52-Week Range:
$2.87
$14.11
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
12.50 | 1.13B | 0 | -56.88M | -39.43M | -0.6604 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
View All
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Enterprise value to EBITDA forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Enterprise value to revenue forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
H.C. Wainwright reiterates Alpha Tau Medical stock rating at buy - Investing.com
Alpha Tau Medical Ltd. (DRTS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alpha Tau Medical Ltd. (DRTS) stock price, news, quote and history - Yahoo Finance UK
DRTS Stock Price, Quote & Chart - ChartMill
Alpha Tau rises on Alpha DaRT head and neck cancer data - Seeking Alpha
Alpha Tau reports positive trial results for cancer therapy combo By Investing.com - Investing.com South Africa
Alpha Tau Posts Strong Alpha DaRT–Keytruda Data in Head and Neck Cancer Study - TipRanks
Alpha Tau reports positive trial results for cancer therapy combo - Investing.com
100% cancer response in Alpha DaRT trial for Alpha Tau Medical (Nasdaq: DRTS) - Stock Titan
All 9 Evaluable Patients Responded in Alpha Tau Cancer Trial - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Alpha Tau Medical (DRTS) Reaches ADMIRE Milestone, Is The Stock Now Fully Valued? - simplywall.st
DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week - Stocktwits
H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment By Investing.com - Investing.com South Africa
Alpha Tau Medical (DRTS) Is Up 6.6% After First Immunocompromised cSCC Patient Treated With Alpha DaRT - simplywall.st
H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
DRTS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center - The Manila Times
Alpha Tau Medical (Nasdaq: DRTS) treats first ADMIRE trial patient with Alpha DaRT - Stock Titan
Alpha Tau's Trial Studies Skin Cancer in Immunocompromised Patients - Stock Titan
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Top Executive Makes Bold Move in Alpha Tau Medical’s Latest Insider Trade - TipRanks
Alpha Tau Medical stock tracks a thin session. Investors watch its listing and filings. - ad-hoc-news.de
Alpha Tau Medical: Alpha Particles Are Still Interesting, But Beware The Hype (NASDAQ:DRTS) - Seeking Alpha
Alpha Tau Medical (DRTS) CFO trades 2,270 shares in exercise and sale - Stock Titan
Enterprise value to revenue forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
Price to sales forward of Alpha Tau Medical Ltd. – BOATS:DRTS - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
Major Insider Move at Alpha Tau Medical Shakes Up Investor Buzz - TipRanks
Enterprise value to EBIT forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
Insider Sell: Raphi Levy Sells Shares of Alpha Tau Medical Ltd (DRTS) - GuruFocus
Enterprise value to EBITDA forward of Alpha Tau Medical Ltd. – BOATS:DRTS - TradingView
Alpha Tau Medical (DRTS) Is Up 17.9% After First International Alpha DaRT Glioblastoma Procedure – Has The Bull Case Changed? - simplywall.st
Form 144 Alpha Tau Medical Ltd. For: 6 July By Investing.com - Investing.com Nigeria
Alpha Tau Medical (DRTS) notice: 20,000 shares from option exercise to be sold - Stock Titan
Alpha Tau Medical (DRTS) CFO exercises 17,873 options and sells 17,873 shares - Stock Titan
Alpha Tau Medical (DRTS) price target increased by 15.15% to 9.69 - MSN
Alpha Tau Medical (NASDAQ: DRTS) CFO sells 2,127 shares after exercising options - Stock Titan
Form 144 Alpha Tau Medical Ltd. For: 2 July By Investing.com - Investing.com Nigeria
Levy Raphi to sell 20,000 Alpha Tau shares (DRTS) via Form 144 - Stock Titan
Alpha Tau Medical Ltd. Warrant 2022-07.03.27 on Alpha Tau Med Rg-A Financial Disclosures & SEC Filings - TradingView
Major Insider Move at Alpha Tau Medical Ltd Shakes Up Investor Watchlists - TipRanks
Insider Sell: Raphi Levy Sells 20,000 Shares of Alpha Tau Medica - GuruFocus
Alpha Tau Medical (DRTS) CFO sells 20,000 shares, retains 90,180 - Stock Titan
Alpha Tau Medical stock hits 52-week high at $11.64 By Investing.com - Investing.com South Africa
Alpha Tau Medical stock hits 52-week high at $11.64 - Investing.com UK
Form 144 Alpha Tau Medical Ltd. For: 30 June By Investing.com - Investing.com South Africa
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Tau Medical Ltd Stock (DRTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levy Raphi | Chief Financial Officer |
Jul 06 '26 |
Sale |
14.00 |
2,270 |
31,782 |
90,180 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):